Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2016
At a glance
- Drugs Influenza-immune-globulin-Emergent-BioSolutions (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Therapeutic Use
- Acronyms INSIGHT 006
- 11 Feb 2016 United Kingdom Clinical Research Network record mentions planned end date as 2 Jan 2017; kept as 1 Oct 2017 as per NCT record.
- 28 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 10 Dec 2014 Planned initiation date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.